02/11/2026
Interesting development in cancer research
The National Cancer Institute (NCI) has announced a new preclinical study to examine ivermectin’s potential effects on cancer cells.
According to NCI leadership, the decision was driven by accumulating laboratory data and growing public interest- enough to warrant a direct, independent evaluation. Results are expected in the coming months.
The timing is notable.
This comes as renewed attention is being paid to repurposed, off-patent medications in oncology, and as discussions continue around expanding research into affordable treatment options rather than relying solely on high-cost therapies.
At the same time, Florida has allocated $60 million in state funding for ivermectin cancer research, with signals that it could support innovative clinical efforts.
For years, preclinical studies have suggested that ivermectin may induce cancer cell death and slow tumor growth in multiple models. Despite that, the drug has remained controversial and largely sidelined.
To be clear: ivermectin is not being labeled a cure.
But its long safety history, low cost, and global availability mean that if any benefit is confirmed, the implications could be significant—especially for access and equity in cancer care.
This could open the door for the other 300+ repurposed drugs!
This moment highlights something important: science should be willing to investigate every credible lead, even those that were once unpopular or dismissed.
Patients deserve transparency, curiosity, and honest evaluation of all legitimate possibilities in the fight against cancer.
What’s your take?
Is this a long-overdue course correction—or something else entirely?r th
